Avantax Advisory Services Inc. Lowers Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Avantax Advisory Services Inc. reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 15.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,483 shares of the medical research company’s stock after selling 1,529 shares during the period. Avantax Advisory Services Inc.’s holdings in IQVIA were worth $1,667,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Synergy Asset Management LLC purchased a new stake in IQVIA during the 4th quarter valued at about $33,000. Avior Wealth Management LLC grew its holdings in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares during the last quarter. Assetmark Inc. increased its position in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares in the last quarter. Meeder Asset Management Inc. raised its holdings in IQVIA by 353.7% in the 3rd quarter. Meeder Asset Management Inc. now owns 245 shares of the medical research company’s stock worth $58,000 after acquiring an additional 191 shares during the last quarter. Finally, Versant Capital Management Inc raised its holdings in IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after acquiring an additional 93 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. UBS Group reduced their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. Barclays decreased their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Stifel Nicolaus dropped their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Morgan Stanley boosted their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Finally, Stephens started coverage on shares of IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price for the company. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Stock Down 0.3 %

IQV opened at $184.64 on Tuesday. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $256.34. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a market cap of $32.55 billion, a price-to-earnings ratio of 24.62, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The firm’s fifty day moving average is $196.34 and its 200 day moving average is $209.96.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.